ECLS in Cardiogenic Shock Complicating Acute Myocardial Infarction: Benefit and Harm

link.springer.com September 11, 2024

Cardiogenic shock is a critical condition that affects up to 10% of patients hospitalized with acute myocardial infarction (AMI), representing the primary cause of death in this group.

Recently, frequentist analysis showed no statistically significant treatment effect for the primary outcome in the randomized ECLS-SHOCK trial comparing extracorporeal life support (ECLS) with medical treatment in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS).

We performed a Bayesian re-analysis using individual patient data allowing quantification of probabilities of benefits and harms.

The results (Electronic Supplementary Material (ESM) Table S1) showed a median RR of 1.00 (95% highest posterior density (HPD) interval 0.79–1.24) for the skeptical prior, with less than 1% probability of a large benefit, and 62% within the ROPE.